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Introduction
Obesity is a complex multifactorial disease, with an incidence that has reached epidemic proportions. Fea-
tures of  obesity-induced metabolic and inflammatory diseases include accumulation of  ectopic fat in key 
insulin-sensitive organs, inflammation of  white adipose tissue (AT), and infiltration of  proinflammatory 
macrophages, all contributing to the development of  insulin resistance, type 2 diabetes (T2D), cardiovascu-
lar and neurodegenerative diseases, and cancer (1). 
AT is a complex and dynamic endocrine organ and a master regulator of  whole-body homeostasis 
through release of  adipokines, lipids, metabolites, noncoding RNAs, and extracellular vesicles (EVs), which 
act on metabolic tissues to regulate lipid and glucose homeostasis. However, whereas healthy AT has a posi-
tive systemic effect, the secretion of  adipocyte-specific factors is often dysregulated with obesity, contributing 
Extracellular vesicles (EVs) are implicated in the crosstalk between adipocytes and other metabolic 
organs, and an altered biological cargo has been observed in EVs from human obese adipose tissue 
(AT). Yet, the role of adipocyte-derived EVs in pancreatic β cells remains to be determined. Here, we 
explored the effects of EVs released from adipocytes isolated from both rodents and humans and 
human AT explants on survival and function of pancreatic β cells and human pancreatic islets. EVs 
from healthy 3T3-L1 adipocytes increased survival and proliferation and promoted insulin secretion 
in INS-1E β cells and human pancreatic islets, both those untreated or exposed to cytokines or 
glucolipotoxicity, whereas EVs from inflamed adipocytes caused β cell death and dysfunction. 
Human lean adipocyte-derived EVs produced similar beneficial effects, whereas EVs from obese 
AT explants were harmful for human EndoC-βH3 β cells. We observed differential expression of 
miRNAs in EVs from healthy and inflamed adipocytes, as well as alteration in signaling pathways 
and expression of β cell genes, adipokines, and cytokines in recipient β cells. These in vitro results 
suggest that, depending on the physiopathological state of AT, adipocyte-derived EVs may 
influence β cell fate and function.
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to low-grade chronic inflammation and insulin resistance (1–3). Indeed, AT-derived inflammatory cytokines 
(CKs), as well as circulating free fatty acids (FFA) and high levels of  glucose, all cause pancreatic β cell apop-
tosis and contribute to the loss of  β cell mass and function, characteristics of  T2D (4, 5). Moreover, behavior-
al differences exist among AT depots, as visceral fat has been associated with metabolic dysfunction, while 
subcutaneous AT (SAT) has been associated with beneficial effects on metabolism (1, 6).
EVs are membrane-bound particles released from all types of  cells and important mediators of  inter-
cellular communication among different organs and tissues. They deliver proteins, mRNAs, and noncoding 
RNAs, such as miRNAs, to recipient cells, thereby modulating their phenotype. EVs are involved in many 
physiological processes and in the pathogenesis of  different diseases, including metabolic and neurodegen-
erative diseases and cancer (7). Moreover, the nature of  their bioactive cargo is heavily dependent on the 
cell of  origin, its physiopathological state, and the stimulus for release (8, 9).
EVs and their components have been identified as potential diagnostic and prognostic biomarkers in 
metabolic diseases. Indeed, EVs from in vitro human differentiated adipocytes and SAT and omental AT 
(OAT) explants express different adipocyte-specific proteins and immune factors (8, 10–12). Moreover, altered 
miRNA profiles have been described in EVs from patients with obesity and metabolic syndrome (8, 13, 14).
EVs isolated from SAT and OAT were found to promote the differentiation of  monocytes to inflamma-
tory macrophages and to reduce insulin signaling in hepatocytes and muscle cells (10, 11). Moreover, EVs 
from AT of  ob/ob mice induced macrophage infiltration into AT and liver and caused insulin resistance 
(15). Similarly, EVs from AT macrophages of  obese mice induced insulin resistance, whereas those from 
lean mice increased insulin sensitivity in obese mice (16). Furthermore, while EVs from adipose-derived 
stem cells of  lean individuals or from mice fed with normal diet exhibited regenerative properties and ben-
eficial metabolic effects, EVs from individuals with obesity and T2D showed reduced therapeutic potential 
(17–19). Overall, these findings suggest that both AT depot and the physiopathological state of  the donor 
influence EV cargo and its effects in recipient cells.
The content of  EVs released by rat and human pancreatic islets and β cells in both normal and stress 
conditions and their effects in recipient cells, including β cells, islet endothelial cells, and immune cells, 
have been recently studied (20–22). The EV-mediated crosstalk between different cell types and pancreatic 
islets/β cells has been also reported. Indeed, human T lymphocyte–derived EVs induced apoptosis in β 
cells and promoted type 1 diabetes (T1D) in mice (23). In addition, EVs from endothelial progenitor cells 
enhanced neoangiogenesis in human pancreatic islets (24), whereas EVs from insulin-resistant muscles 
influenced gene expression and proliferation in mouse β cells (25). However, the EV-mediated crosstalk 
between adipocytes and pancreatic β cells remains unexplored.
In the present study, we describe the effects of  EVs isolated from healthy or inflamed rodent and human 
adipocytes on survival, proliferation, and function of  rodent and human β cells and human pancreatic 
islets, untreated or exposed to diabetogenic stimuli. We also show the role of  EVs obtained from human 
lean and obese AT explants on human β cell fate and function. The survival and metabolic pathways, along 
with expression of  β cell genes, adipokines and CKs, were assessed in EV-treated β cells, as well as the dif-
ferential expression of  miRNAs in EVs. Our findings suggest the existence of  an EV-mediated functional 
crosstalk between AT and pancreatic β cells, which positively or negatively influences β cell fate, depending 
on the physiopathological state of  adipocytes and AT of  origin.
Results
EVs isolated from 3T3-L1 adipocytes and human SAT transport adipocyte-specific genes and proteins. EVs isolat-
ed from 3T3-L1 adipocytes (Ad-EVs) and human SAT (SAT-EVs) were isolated by ultracentrifugation 
from 3T3-L1 adipocytes and human SAT, respectively. To assess their number and size, both types of  
EVs were first analyzed by nanoparticle tracking analysis (NTA) (Figure 1, A and B). Their round-
shape morphology and size were further confirmed by transmission electron microscopy (TEM) (Figure 
1, A and B, insets). We observed variability in the size of  EVs, depending on whether they were studied 
by NTA or TEM, likely because of  the influence of  temperature and Brownian motion for NTA, and 
fixation of  EVs for TEM. Western blot analysis showed expression of  the EV markers Alix, CD9, and 
CD63 in both Ad-EVs and SAT-EVs (Figure 1, C and D). Adipocyte-specific proteins and mRNAs, 
such as adiponectin, leptin, fatty acid–binding protein 4 (FABP4), and PPARγ, were detected in both 
3T3-L1 cells (Figure 1, E and G) and SAT (Figure 1, F and H) and, although in lower amount, also in 
their respective EVs, except PPARγ, which was absent in SAT-EVs.
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EVs from normal or inflamed 3T3-L1 adipocytes produce opposite effects on survival and function of  pancreatic 
β cells. To assess the biological effects of  Ad-EVs in β cells, we first explored whether Ad-EVs were effi-
ciently internalized by INS-1E β cells. Ad-EVs labeled with PKH26 dye were incorporated by β cells and 
accumulated at the perinuclear area after 6, 12, and 24 hours (Figure 2A, top). However, pretreatment 
with anti-CD29 blocking antibody inhibited internalization (Figure 2A, bottom), suggesting a role for 
adhesion molecules in Ad-EV uptake by β cells. We next investigated the effect of  Ad-EVs on survival and 
function of  β cells. INS-1E β cells were cultured in the absence of  serum and challenged with different 
doses of  Ad-EVs. From 10 to 15 × 103/cell, Ad-EVs counteracted serum deprivation–induced cell death, 
suggesting survival effects (Supplemental Figure 1A; supplemental material available online with this arti-
cle; https://doi.org/10.1172/jci.insight.141962DS1). Based on these findings, 10 × 103 was selected as 
the EV concentration for subsequent experiments. The role of  Ad-EVs was next studied in β cells cultured 
in the presence of  TNF-α, IL-1β, and IFN-γ, whose synergism has been implicated in β cell death and 
Figure 1. Characterization of EVs released from 3T3-L1 adipocytes and human subcutaneous adipose tissue. Analysis of 
size distribution, showing the size and number of EVs released from 3T3-L1 adipocytes (Ad-EVs) (A) and human subcutane-
ous adipose tissue (SAT-EVs) (B) using the NanoSight technology (n = 3). Insets show representative micrographs obtained 
by TEM of purified Ad-EVs and SAT-EVs (scale bar: 100 nm). (C and D) Representative Western blot images for EV markers 
Alix, CD9, and CD63 in 3T3-L1 adipocytes and Ad-EVs (C) and in SAT and SAT-EVs (D) (n = 3). (E and F) Representative West-
ern blot for adiponectin, leptin, FABP4, and PPARγ in 3T3-L1 cells and Ad-EVs (E) and in SAT and SAT-EVs (F). Actin served 
as internal control (n = 3). (G and H) Representative gene expression for adiponectin, leptin, FABP4, PPARγ1, and PPARγ2 in 
3T3-L1 and Ad-EVs (G) and in SAT and SAT-EVs (H), as assessed by RT-PCR. 18s rRNA served as internal control (n = 3).
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dysfunction in both T1D and T2D (4, 26, 27). Untreated and CK-treated β cells were challenged with 
Ad-EVs or EVs from 3T3-L1 adipocytes exposed to the same combination of  CKs (CK-EVs). Indeed, 
elevation of  inflammatory CKs in obesity and T2D causes adipocyte dysfunction and insulin resistance in 
AT, inflammation, and metabolic damage (1, 3). Ad-EVs from untreated adipocytes increased cell survival 
Figure 2. Effect of Ad-EVs and CK-EVs on survival, proliferation, apoptosis, and function of INS-1E β cells. (A) Top: Representative fluorescence micros-
copy micrographs showing internalization of Ad-EVs in INS-1E β cells, incubated at the indicated times with unlabeled Ad-EVs (Control) or with Ad-EVs 
labeled with PKH26 (red dye) (scale bar: 10 μm). Bottom: Internalization of Ad-EVs for 24 hours in cells untreated (-CD29) or preincubated for 1 hour with 
the blocking antibody against CD29 (+CD29). Nuclei were stained blue with DAPI (scale bar: 10 μm). Cell survival (B), cell proliferation (C), and apoptosis (D) 
assessed by MTT, BrdU, and caspase-3 activity, respectively, in cells cultured in serum-deprived medium for 12 hours, then untreated (control [c]) or treated 
for a further 24 hours with Ad-EVs (10 × 103/cell) or with EVs from 3T3-L1 adipocytes treated for 24 hours with cytokines (CKs) (CK-EVs) (TNF-α/IFN-γ/IL-1β 
[50, 25, and 2.5 ng/mL, respectively]). (E) Cell survival in cells treated for 24 hours with or without Ad-EVs and anti-CD29 antibody. Results are expressed 
as percentage of control (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001 vs. c; ##P < 0.01, ###P < 0.001 by 1-way ANOVA and Tukey’s post hoc test (n = 5 
for B and C; n = 3 for D; n = 4 for E). Cell survival (F), cell proliferation (G), and apoptosis (H) assessed by MTT, BrdU, and caspase-3 activity, respectively, in 
β cells cultured in serum-deprived medium or pretreated for 40 minutes with CKs (TNF-α/IFN-γ/IL-1β [100, 50 and 5 ng/mL, respectively]), and then with 
EVs or CK-EVs for 24 hours. (I) Cell survival in cells cultured with or without CKs, Ad-EVs, and CD29 blocking antibody. Results are expressed as mean ± 
SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. CK; ##P < 0.01, ###P < 0.001 by 1-way ANOVA and Tukey’s post hoc test (n = 5 for F and G; n = 3 for H; n = 4 for 
I). (J and K) Insulin secretion assessed by ELISA in INS-1E β cells incubated with 2 mM glucose for 1 hour and for a further 1 hour with the indicated concen-
trations of glucose, in the presence or absence of Ad-EVs (J) or CK-EVs (K) (mean ± SEM). *P < 0.05 by 2-tailed Student’s t test (n = 3).
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and proliferation and reduced apoptosis, assessed as caspase-3 activity, in serum-deprived cells (Figure 2, 
B–D). Similar effects were obtained in CK-treated β cells, except for apoptosis that was not blunted by 
Ad-EVs, compared with CKs alone (Figure 2, F–H). As opposed to Ad-EVs, CK-EVs reduced cell surviv-
al and proliferation and increased apoptosis in serum-starved cells (Figure 2, B–D); furthermore, CK-EVs 
exacerbated the detrimental effects of  CKs in β cells, including an effect on apoptosis (Figure 2, F–H). 
Of  note, pretreatment with anti-CD29 antibody, while having no effect per se, blocked the survival action 
of  Ad-EVs, under both serum starvation and treatment with CKs (Figure 2, E and I). The functions of  
Ad-EVs and CK-EVs were assessed also in β cells exposed to glucolipotoxicity, which adversely affects β 
cell function and survival in T2D (4). Ad-EVs increased, while CK-EVs reduced, survival and prolifera-
tion of  β cells treated with high concentrations of  glucose and palmitate (Supplemental Figure 1, B and 
C). Anti-CD29 antibody attenuated the survival effects of  Ad-EVs, in line with the results observed for 
serum starvation and CK synergism (Supplemental Figure 1D).
Ad-EVs also slightly increased glucose-stimulated insulin secretion (GSIS), at 7.5, 15, and 25 mM 
glucose (Figure 2J), whereas CK-EVs inhibited GSIS at the highest glucose concentrations tested (15 and 
25 mM) (Figure 2K), in agreement with the results on cell survival and proliferation. Overall, these data 
indicate that EVs derived from healthy adipocytes are beneficial, whereas EVs from inflamed adipocytes 
are harmful for β cells, and furthermore, internalization by β cells is essential for EVs to display their effects.
Ad-EVs and CK-EVs modulate survival and unfolded protein response pathways in pancreatic β cells as well 
as expression of  β cell– and adipocyte-specific genes and CKs. The signaling pathways involved in the effects 
of  Ad-EVs and CK-EVs in β cells were next studied. Treatment of  INS-1E β cells for 24 hours with 
Ad-EVs increased, whereas CK-EVs reduced, the phosphorylation of  Akt (Figure 3A), its downstream 
target GSK-3β (Figure 3B), and MAPK ERK1/2 (Figure 3C), key pathways regulating survival, pro-
liferation, and function of  β cells (28). We then analyzed the effects of  EVs on the unfolded protein 
response (UPR), an adaptive response of  the cells to the disruption of  endoplasmic reticulum (ER) 
homeostasis. In β cells the UPR, which is activated by elevated levels of  FFAs/glucose or CKs, among 
others, can restore protein folding, cell function, and survival; however, when unable to compensate, 
it ultimately leads to apoptotic cell death (29, 30). Ad-EVs, and to a greater extent CK-EVs, increased 
the phosphorylation of  PKR-like ER kinase (PERK) and its downstream effector, eukaryotic initiation 
factor 2α (eIF2α) (Figure 3, D and E). Furthermore, CK-EVs but not Ad-EVs, promoted the phosphor-
ylation of  c-Jun N-terminal kinase (JNK) (Figure 3F), which can be activated by the UPR component 
inositol-requiring protein 1α (IRE1α). Importantly, only CK-EVs were able to increase the mRNA levels 
of  the proapoptotic transcription factor C/EBP homologous protein (CHOP) (Figure 3G), whose activ-
ity is promoted by both PERK/eIF2α and IRE1α/JNK (31).
With regards to the regulation of  β cell genes, Ad-EVs and CK-EVs, respectively, promoted and blunt-
ed the expression of  transcription factors essential for β cell differentiation/maturation and β cell function 
and identity, such as pancreatic and duodenal homeobox 1 (Pdx1) and Nkx6.1 (32) (Figure 3, H and I). We 
then assessed the presence of  adipocyte-specific mRNAs in INS-1E β cells, such as Adipoq, encoding for 
adiponectin, which positively modulates β cell survival (2); Lep, whose product, leptin, has antiapoptotic 
effects on β cells but inhibits GSIS (2); and complement factor D (Cfd), encoding for adipsin, which stim-
ulates GSIS (33). Adiponectin gene expression was strongly increased in cells exposed to Ad-EVs; expres-
sion of  leptin and adipsin was also increased, though to a lesser extent, also increased the mRNA levels 
of  these adipokines (Figure 3, J–L). To clarify its potential survival role, adiponectin protein levels were 
measured in conditioned medium of  INS-1E cells, either untreated or treated with Ad-EVs or CK-EVs. 
Adiponectin was undetectable in β cells in all conditions (data not shown), whereas it was produced by 
3T3-L1 adipocytes, which were used as positive control (2.193 ± 0.092 ng/mL, n = 3).
The effects of  EVs in β cells were paralleled by changes in expression of  CK genes. Indeed, while 
Ad-EVs had no effect on Tnfa (encoding TNF-α) and Ifng (encoding IFN-γ), CK-EVs upregulated the 
expression of  both CKs, whereas Il1b (encoding IL-1β) was unchanged after treatment with both Ad-EVs 
and CK-EVs (Figure 3, M–O). These results indicate that in β cells Ad-EVs and CK-EVs differently modu-
late survival and ER stress pathways as well as expression of  β cell genes, adipokines, and CKs.
miRNAs are differentially expressed in Ad-EVs and CK-EVs. To evaluate whether the EV cargo of  small 
RNAs, in particular miRNAs, was different according to the treatment, the RNAs extracted from Ad-EVs 
and CK-EVs were sequenced for their small RNA content (small RNA-seq). EVs from 3 cultures for each 
treatment were sequenced. A median of  2.00 million raw reads were generated for the 6 samples analyzed. 
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We found 53 miRNAs differentially expressed between Ad-EVs and CK-EVs. Of these, 27 were upregulated 
and 26 downregulated in CK-EVs compared with Ad-EVs (Figure 4 and Supplemental Table 5). The set of  
validated target genes for the miRNAs differentially expressed between Ad-EVs and CK-EVs was extracted 
with miRWalk database version 3 (34). 53 miRNAs had 422 validated target genes (213 unique genes), which 
Figure 3. Regulation of signaling pathways and expression of β cell genes, adipokines, and CKs in INS-1E β cells 
treated with Ad-EVs and CK-EVs. Representative Western blots for phosphorylated Akt (P-Akt) (A), P-GSK-3β (B), 
P-ERK1/2 (C), P-PERK (D), P-eIF2α (E), and P-JNK (F) in cells untreated (control [c]) or treated with Ad-EVs or CK-EVs 
for 24 hours (top). Blots were reprobed with nonphosphorylated antibodies for normalization (bottom). Results are 
expressed as a percentage of control untreated cells (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001 vs. c; #P < 0.05, 
###P < 0.001 by 1-way ANOVA and Tukey’s post hoc test (n = 3). Real-time PCR for the UPR gene Chop (G) and for β cell 
genes, Pdx1 (H) and Nkx6.1 (I); adipokines: adiponectin (Adipoq) (J), leptin (Lep) (K), and adipsin (Cfd, complement fac-
tor D) (L); and CKs: TNF-α (Tnfa) (M), IFN-γ (Ifng) (N), and IL-1β (Il1b) (O) in β cells untreated or treated with Ad-EVs or 
CK-EVs for 24 hours (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001 vs. c; #P < 0.05, ##P < 0.01, ###P < 0.001 by 1-way 
ANOVA and Tukey’s post hoc test (n = 3 for G–I and M–O; n = 5 for J–L).
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were tested for overrepresentation using a gene set enrichment analysis (GSEA) program implemented in the 
new version of  miRWalk. The Kyoto Encyclopedia of  Genes and Genomes (KEGG) showed several path-
ways to be significantly enriched, including the AGE/RAGE signaling pathway in diabetic complications 
and Toll-like receptor and PI3K/Akt signaling pathways (Supplemental Table 6). The Gene Ontology (GO) 
database showed that several of  the target genes were significantly enriched for biological processes implicat-
ed in systemic inflammation and insulin resistance (Supplemental Table 7). We further analyzed those val-
idated miRNAs targeting genes that were altered in β cells after treatment with Ad-EVs and CK-EVs (Sup-
plemental Table 8). Overall, we observed a substantial inverse expression between miRNAs and their target 
mRNAs. For example, whereas TNFA and IFNG mRNAs were increased in β cells treated with CK-EVs 
(Figure 3, M and N), the miRNAs targeting these genes (mmu-miR-296-3p, mmu-miR-298-5p, and mmu-
miR-351-5p for TNF-α, and mmu-miR-125a-5p for IFN-γ) were downregulated (Supplemental Table 8). 
These results suggest that the downregulation of  specific miRNAs allows an upregulation of  their target 
genes and implicates a complex crosstalk between adipocytes and β cells, involving a miRNA-dependent 
posttranscriptional gene regulation in β cells.
Ad-EVs, but not CK-EVs, increase cell survival in human pancreatic islets. The effects of  Ad-EVs and CK-EVs 
were subsequently assessed in human pancreatic islets. Confocal microscopy analysis showed that incorpo-
ration of  PKH26-labeled Ad-EVs increased at 6 and 24 hours, when the majority of  islet cells were positive 
for the red dye (Figure 5A). Staining of  Ad-EVs also revealed partial colocalization with insulin, indicating 
uptake by β cells. Furthermore, pretreatment with anti-CD29 antibody strongly reduced internalization of  
Ad-EVs (Supplemental Figure 2A). As for INS-1E β cells, we evaluated the role of  Ad-EVs and CK-EVs on 
survival of  islets cultured in the absence of  serum or in the presence of  CKs for 72 hours. Ad-EVs increased 
cell survival in both conditions, whereas CK-EVs exacerbated the detrimental effects of  serum starvation 
and CKs (Figure 5, B and C). Similarly, Ad-EVs promoted, whereas CK-EVs reduced, cell survival after 
treatment with high glucose and palmitate (Supplemental Figure 2B). In addition, Ad-EVs increased GSIS 
at all the glucose concentrations tested (Figure 5D). Due to the limited availability of  human islets, GSIS 
was not assessed in islets treated with CK-EVs.
EVs from human lean AT exert positive effects, whereas EVs from obese AT show negative effects on survival and 
function of  human β cells. The effects of  human AT-derived EVs were then assessed in the human pancreatic 
β cell line, EndoC-βH3. EVs from SAT-EVs were internalized by EndoC-βH3 cells, as demonstrated by 
PKH26 staining (Figure 6A, top), whereas pretreatment with anti-CD29 antibody strongly reduced their 
incorporation (Figure 6A, bottom). We then verified whether EVs from lean or obese individuals differently 
affected survival and function of  β cells. EVs were isolated from both in vitro–differentiated adipocytes 
and ex vivo AT explants. In line with the previous results on 3T3-L1–derived EVs, EVs from in vitro–
differentiated subcutaneous lean adipocytes (sAd-EVs) increased survival of  β cells cultured in normal 
medium, compared with control cells (Figure 6B), whereas no effect was observed in β cells treated with 
CKs (Figure 6C). sAd-EVs also slightly promoted GSIS at 15 and 25 mM glucose (Figure 6D). Conversely, 
EVs from CK-treated lean subcutaneous differentiated adipocytes (sCK-EVs) reduced survival of  β cells, 
cultured both without or with CKs (Figure 6, B and C). In addition, sCK-EVs, but not sAd-EVs, increased 
the expression of  TNFA, IFNG, and IL1B (Figure 6, E–G). In line with their positive effects, sAd-EVs 
increased PDX1 and NKX6.1 mRNA in human β cells (Supplemental Figure 3, A and B) and upregulated 
ADIPOQ and CFD (adipsin) (Supplemental Figure 3, C and E). By contrast, sCK-EVs inhibited Pdx-1 gene 
expression and showed a mild effect on elevation of  adiponectin, leptin, and adipsin (Supplemental Figure 
3, C–E). Unlike EVs from sAd-EVs, EVs from lean SAT-EVs showed no effect on cell survival and GSIS 
(Supplemental Figure 3, F–H). We found 20 miRNAs differentially expressed between sCK-EVs and sAd-
EVs, 17 upregulated, and 3 downregulated (Supplemental Figure 4 and Supplemental Table 9). GO analy-
sis showed enrichment of  target genes involved in biological processes, including negative regulation of  cell 
cycle process, negative regulation of  transcription and positive regulation of  stress-activated protein kinase 
signaling cascade (Supplemental Table 10). However, no inverse expression between human miRNAs and 
their target mRNAs was observed (Supplemental Table 8).
We next investigated the impact of  EVs obtained from AT explants of  individuals with obesity. 
As opposed to EVs from differentiated lean adipocytes, EVs from both obese subcutaneous (SAT-EVs) 
and OAT (OAT-EVs) equally reduced survival of  human β cells, untreated (Figure 6H) or treated with 
CKs (Figure 6I). Furthermore, they similarly blunted GSIS at 15 and 25 mM glucose (Figure 6J). We 
then analyzed the effect of  obese and lean EVs on gene expression of  CKs, β cell transcription factors, 
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and adipokines in β cells, using only subcutaneous-derived EVs, because of  the limited availability of  
OAT. TNFA mRNA was unchanged in β cells treated with lean SAT-EVs but increased by obese SAT-
EVs, compared with untreated cells (Figure 6K). Similarly, although slightly increased by lean SAT-EVs, 
obese SAT-EVs strongly upregulated IFNG (Figure 6L), whereas IL1B levels were equally upregulated 
(Figure 6M). Lean, but not obese, SAT-EVs enhanced expression of  PDX1 and NKX6.1 mRNAs (Sup-
plemental Figure 3, I–J), consistent with the results previously observed for sAd-EVs (Supplemental 
Figure 3, A and B). Moreover, lean, more than obese, SAT-EVs increased adiponectin gene expression 
(Supplemental Figure 3K). Leptin was markedly upregulated by obese SAT-EVs, and upregulated far less 
by lean SAT-EVs, and adipsin was increased only by lean SAT-EVs (Supplemental Figure 3, L and M). 
Figure 4. Heat map displaying the significantly differentially expressed miRNAs in Ad-EVs and CK-EVs. Each row represents a miRNA and each column 
a sample. The sample dendrogram, generated in an unsupervised way from the expression profiles, is shown at the top. The heat map color shows the 
log2 fold change normalized expression of each sample with respect to the mean expression (across samples) for each miRNA. The color scale on the right 
correspond to high (red), medium (yellow), and low (blue) expression, respectively.
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Hence, similar to 3T3-L1–derived EVs, EVs from human subcutaneous differentiated adipocytes exert 
beneficial effects, whereas EVs from the same adipocytes pretreated with CKs are detrimental for β cells. 
Furthermore, EVs from obese, but not from lean, AT explants are harmful for β cells.
Discussion
The adipokine-mediated crosstalk between adipocytes and other cell types, including immune cells and 
insulin-responsive cells, is a key mechanism regulating whole-body homeostasis (2). More recently, a rel-
evant role in the communication between fat cells and other cell types has been attributed to AT-derived 
EVs (8); however, their effect on survival and function of  pancreatic β cells remains unexplored. Here, we 
show that EVs from 3T3-L1 adipocytes increase survival and proliferation, reduce apoptosis, and positively 
influence GSIS in INS-1E β cells and human pancreatic islets, both those untreated or exposed to diabeto-
genic stimuli. In addition, by using anti-CD29 antibody, we demonstrate that uptake by β cells and inter-
nalization are essential for EVs to display their survival effects. Similarly, EVs from differentiated human 
lean adipocytes displayed beneficial activities in human EndoC-βH3 cells treated under the same stress 
conditions. By contrast, EVs from both 3T3-L1 and differentiated human lean adipocytes pretreated with 
CKs, as well as AT EVs from human obese individuals, reduced survival and function in rodent and human 
β cells. These effects were paralleled by differential expression of  miRNAs in EVs, as well as modulation of  
survival and metabolic pathways in β cells and regulation of  genes specific for β cells, adipokines, and CKs.
As previously demonstrated (11, 35, 36), we observed that EVs from both 3T3-L1 adipocytes and 
human SAT express markers for both EVs and adipocytes, such as adiponectin and leptin. Accordingly, 
fully functional AT was previously found to protect other metabolic organs from the harmful effect of  
dyslipidemia, in part through the beneficial role of  adiponectin and adipsin (2). Moreover, EVs from lean 
Figure 5. Effect of Ad-EVs and CK-EVs on survival and function of human pancreatic islets. (A) Representative confocal microscopy images of human 
pancreatic islets incubated with PKH26-labeled Ad-EVs at the times indicated. Ad-EVs are shown in red, DAPI-stained nuclei in blue, and insulin in green 
for β cells. Merge at 6 and 24 hours shows colocalization of Ad-EVs and insulin (yellow) in β cells, as indicated by arrows (scale bar: 50 μm). (B) Cell survival 
assessed by Alamar blue assay in islets cultured for 72 hours in normal medium with serum (s) or in serum-deprived medium alone (c) or with either Ad-EVs 
(1 × 108/islet) or CK-EVs (1 × 108/islet). (C) Cell survival in islets cultured in serum-deprived medium (control [c]) or exposed to cytokines (CK) (TNF-α/IFN-γ/
IL-1β, 5 ng/mL each) and either untreated or treated with Ad-EVs or CK-EVs for 72 hours. Results for B and C are expressed as a percentage of control for B 
and percentage of CK for C (mean ± SEM) (n = 5). ***P < 0.001 vs. c (B) or CK (C); ###P < 0.001 by 1-way ANOVA and Tukey’s post hoc test. (D) Insulin secre-
tion assessed by ELISA in pancreatic islets incubated with 2 mM glucose for 1 hour and then for a further 1 hour with the indicated concentrations of glucose, 
in the presence or absence of Ad-EVs (1 × 108/islet) (mean ± SEM) (n = 4). *P < 0.05 at each glucose concentration, by Student’s 2-tailed t test.
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mouse AT macrophages improved glucose tolerance and insulin sensitivity when administered to obese 
mice, whereas those from obese mice were harmful in lean mice (16). Our results also revealed that EVs 
from healthy and inflamed adipocytes differently regulate pathways essential for β cell survival, prolifer-
ation, and function, such as PI3K/Akt, its downstream effector GSK-3β, and ERK1/2 (27, 28). Ad-EVs 
and CKs also modulated the UPR, a pathway activated in response to the disruption of  ER homeostasis, 
in an attempt to restore cellular equilibrium. The UPR includes different pathways, mediated by the action 
Figure 6. Effect of human lean and obese 
AT-derived EVs in human EndoC-βH3 β 
cells. (A) Representative fluorescence 
microscopy micrographs showing subcuta-
neous AT–derived EV (SAT-EV) internaliza-
tion in EndoC-βH3 cells, incubated at the 
indicated times with SAT-EVs unlabeled 
(Control) or labeled with PKH26 (red dye) 
(scale bar: 10 μm). SAT-EV internalization 
(24 hours) in cells untreated or preincubated 
for 1 hour with CD29 antibody. Nuclei were 
stained blue with DAPI (scale bar: 10 μm). 
(B) Cell survival (MTT) in β cells untreated 
(control [c]) or treated for 24 hours with 
lean sAd-EVs (10 × 103/cell) or EVs from lean 
subcutaneous differentiated adipocytes 
pretreated with TNF-α/IFN-γ/IL-1β (50, 
25, and 2.5 ng/mL, respectively) (sCK-
EVs). (C) Cell survival in β cells untreated 
or treated with sAd-EVs or sCK-EVs, then 
with TNF-α/IFN-γ/IL-1β (CK) (20, 20, and 
1 ng/mL, respectively) 24 hours (mean ± 
SEM). *P < 0.05, **P < 0.01 vs. c (B) or vs. 
CK (C); ##P < 0.01 (n = 5), 1-way ANOVA and 
Tukey’s post hoc test. (D) Insulin secretion 
(ELISA) in β cells incubated for 1 hour with 
indicated concentrations of glucose with or 
without sAd-EVs (mean ± SEM). *P < 0.05, 
Student’s 2-tailed t test (n = 3). Real-time 
PCR for TNFA (E), IFNG (F), and IL1B (G) in 
cells untreated or treated with sAd-EVs 
or sCK-EVs (mean ± SEM). *P < 0.05, **P 
< 0.01 vs. c; #P < 0.05, 1-way ANOVA and 
Tukey’s post hoc test (n = 3). Cell survival 
in β cells cultured in normal medium (H) 
or treated with CKs (as for C) (I), and with 
EVs from obese subcutaneous AT (SAT-EVs) 
or obese omental AT (OAT-EVs) (10 × 103/
cell) (mean ± SEM). * P < 0.05, **P < 0.01, 
**P < 0.001 vs. c (H) or vs. CK (I), 1-way 
ANOVA and Tukey’s post hoc test (n = 8). (J) 
Insulin secretion (ELISA) in EndoC-βH3 cells 
incubated as in D in the absence or presence 
of SAT-EVs or OAT-EVs (10 × 103/cell) (mean 
± SEM). *P < 0.05, Student’s 2-tailed t test 
(n = 3). Real-time PCR for TNFA (K), IFNG 
(L), and IL1B (M) mRNA in cells untreated or 
treated with lean or obese SAT-EVs 24 hours 
(mean ± SEM). *P < 0.05, ***P < 0.001 vs. c; 
##P < 0.01, 1-way ANOVA and Tukey’s post 
hoc test (n = 3).
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of  3 signaling proteins, PERK, IRE1α, and activating transcription factor 6 (ATF6). However, under irre-
solvable ER stress, the UPR switches from an adaptive to an apoptotic role (29–31). Importantly, ER stress 
and disrupted UPR have been implicated in the pathophysiology of  both T1D and T2D (37). In addition, β 
cell exposure to proinflammatory CKs induces UPR responses, which in turn may potentiate inflammation 
and promote cell death (29, 31, 38). We found that CK-EVs promoted the phosphorylation of  2 main UPR 
proteins, PERK and its downstream effector eIF2α (PERK/eIF2α), and JNK, which can be phosphory-
lated by IRE1α, as well as CK receptors independently of  the UPR (31, 38). Interestingly, JNK has been 
recently indicated as a key factor regulating the transition from adaptive to apoptotic UPR during ER stress 
induced by CKs (39). Conversely, Ad-EVs only weakly increased PERK/eIF2α activity, while having no 
effect on JNK. These findings can be explained by the fact that PERK/eIF2α can either reduce protein 
overload through decreasing general translational activity or initiate proapoptotic response via ATF4 and 
upregulation of  the proapoptotic UPR effector CHOP. Thus, we hypothesize that Ad-EVs may induce a 
compensatory pathway, while CK-EVs diverts PERK/eIF2α signaling toward the ATF4-mediated increase 
in CHOP expression. This assumption is further sustained by our results on Chop mRNA, which was 
increased by CK-EVs but not Ad-EVs. In addition, only CK-EVs promoted the phosphorylation of  JNK, 
the IRE1α-mediated activity of  which is required for CHOP promoter activation and expression (38, 39).
A crucial role for GSK-3β on insulin secretion has been recently reported, involving a Pdx1-dependent 
mechanism, as well as glucokinase, Glut2, and Nkx.6.1 (27, 40). Accordingly, we found that Ad-EVs, but not 
CK-EVs, increased the phosphorylation, i.e., reduced the activity, of  GSK-3β; in addition, EVs from healthy 
adipocytes and lean SAT, but not from CK-treated adipocytes or obese SAT explants, upregulated Pdx1 and 
Nkx6.1. These transcription factors are essential for β cell differentiation and maintenance of  adult β cell func-
tion, and their activity has been found perturbed in conditions of  metabolic stress (32). Furthermore, many 
studies have demonstrated an association between high adiponectin levels and increased insulin sensitivity, 
β cell function, and survival, whereas obesity and elevation of  inflammatory CKs in AT have been linked to 
reduced adiponectin production (2, 3, 41). In keeping with these findings, both EVs from healthy 3T3-L1 and 
lean SAT-derived differentiated adipocytes strongly upregulated the expression of  adiponectin in INS-1E and 
EndoC-βH3 cells, whereas adiponectin expression was low after exposure to CK-EVs, suggesting horizontal 
gene transfer to β cells. However, we could not find detectable levels of  adiponectin protein in conditioned 
medium of INS-1E β cells challenged with Ad-EVs, indicating that the mRNA levels transferred by EVs are 
not translated into a sufficient amount of  protein to produce an effect in these cells. Similar changes were 
observed for adipsin, an adipokine of  the complement system that stimulates GSIS in β cells and with levels 
that have been found to be reduced in patients with T2D with β cell failure (33). Interestingly, EVs from 
lean SAT explants increased adiponectin and adipsin as well as Pdx-1 and Nkx6.1 mRNA in human β cells, 
despite having no effect on β cell survival. Beside the fact that the protein levels of  adiponectin are likely not 
detectable in human β cells, as observed in INS-1E β cells treated with Ad-EVs, SAT-EVs derive from a mixed 
cell population, including mesenchymal stem cells, fibroblasts, and immune cells, in addition to mature adi-
pocytes (42), which would generate a cargo different from that of  3T3-L1 adipocytes or human differentiated 
adipocytes. Lean SAT-EVs also slightly upregulated IFN-γ and IL-1β but not TNF-α in human β cells, where-
as obese SAT-EVs increased the mRNA levels of  all CKs and leptin but had no effect on β cell genes. Indeed, 
it is known that CKs, particularly TNF-α, but also leptin, which inhibits GSIS and with production that is 
increased in obese SAT, released by obese AT are harmful for β cells (2, 4, 6).
In line with our findings, injection of AT-derived EVs from ob/ob mice into mice fed with both normal and 
high-fat diet induced macrophage activation and upregulation of inflammatory CKs, suggesting that EV cargo 
is altered in obesity and promotes inflammatory responses either locally or at distant sites (15). Furthermore, 
EVs from insulin-resistant muscles of palmitate-treated mice influence gene expression and proliferation, but 
not GSIS, in mouse β cells, contributing to β cell mass adaptation during insulin resistance. However, although 
internalized in pancreatic islets, these EVs were found to be incorporated by other cells types before reaching the 
pancreas (25). At variance with our findings, Kranendonk et al. reported that EVs from both human in vitro–dif-
ferentiated SAT adipocytes and SAT and OAT explants induce the differentiation of monocytes to inflammato-
ry macrophages (11); yet, these EVs derived from both normal and insulin-resistant individuals and, thus, had 
an overall altered cargo. Dysregulated insulin signaling was also observed in the liver and muscle cells after treat-
ment with EVs from SAT and OAT explants of obese patients, overweight patients, and patients with T2D (10).
The results of  this study also suggest a role for miRNAs, as we observed their differential expression 
in EVs from CK-treated adipocytes, compared with untreated adipocytes. miRNAs are noncoding RNAs, 
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acting on target mRNAs to induce their degradation or inhibition of  translation. Interestingly, miRNAs 
are among the main components of  EV cargo and can modulate the function of  neighboring or distant 
recipient cells (7). Moreover, AT-derived EVs are an important source of  miRNAs, and their levels may 
change in diseases with altered fat mass and function, such as obesity and diabetes (13, 43). miRNAs are 
also potent regulators of  β cell biology (44) through the promotion of  β cell dysfunction and death under 
metabolic stress conditions, and their dysregulation has been linked to the development of  T1D and T2D 
(20, 23, 45). We observed that preincubation of  3T3-L1 adipocytes and human subcutaneous differentiated 
lean adipocytes with inflammatory CKs alters miRNA profile in EVs. These changes were paralleled by 
an enrichment in metabolic pathways in EVs derived from CK-treated adipocytes, compared with untreat-
ed adipocytes, and an increase in target genes involved in systemic inflammation and insulin resistance. 
miR-155-5p was the most upregulated miRNA, in agreement with previous reports showing increased 
miR-155-5p levels in TNF-α– or palmitic acid–treated 3T3-L1 adipocytes (14, 46) and its important role on 
glucose and lipid metabolism and β cell function (16, 23, 47, 48). In addition, miR-30a-5p, increased here 
in CK-EVs, has been linked to GSIS and β cell dysfunction, and miR-146 with CK-induced apoptosis in 
β cells (44). Among the downregulated miRNAs in CK-EVs, miR-320-3p and miR-501 have been related 
to the positive effects of  antidiabetic drugs in β cells (49). In both 3T3-L1 and human adipocyte EVs, we 
found differential expression of  miR-7, which is implicated in inhibition of  GSIS and which was found 
at increased levels in cadaveric islets of  diabetic donors (44). Thus, we cannot exclude a role for miRNAs 
in the effects of  adipocyte-derived EVs in β cells; however, miRNAs are likely not solely responsible. It is 
possible that they are part of  a complex mechanism involving other components of  EV cargo.
In conclusion, herein we show that adipocyte-derived EVs positively or negatively influence survival, 
proliferation, and function of  pancreatic β cells and human pancreatic islets in vitro, depending on the state 
of  adipocytes and the origin of  AT. Translated in vivo, healthy AT would evoke beneficial effects, whereas 
in pathological conditions such as obesity and insulin resistance, the crosstalk between adipocytes and 
pancreatic β cells would generate a negative loop, further amplifying the progression of  insulin resistance 
and β cell dysfunction. Understanding the molecular mechanisms involved in EV actions would help the 
design of  new strategies to prevent β cell loss and diabetes. Interestingly, the survival effects observed in 
human pancreatic islets suggest that EVs may act on other islet cell types in addition to β cells; however, 
this intriguing hypothesis requires additional investigation. In 1996, Kieffer et al. proposed the concept of  
adipoinsular axis, which was initially identified with the effects of  leptin in β cells and then extended to the 
biological activities of  many adipokines (2, 50). In agreement with that view, our in vitro findings suggest 
the existence of  a functional adipoinsular axis involving EVs and their cargo as possible regulators of  β cell 
survival and function.
Methods
Cell culture. 3T3-L1 murine preadipocytes (ATCC) were maintained in DMEM (MilliporeSigma) supple-
mented with 10% FCS (Life Technologies). The cells were cultured and differentiated into adipocytes as 
described previously (51). Briefly, 2 days after confluence (day 0), cells were treated with differentiation 
medium (5 μg/mL insulin, 1 μM dexamethasone, and 0.5 mM 3-Isobutyl-1-methylxanthine [IBMX]) in 
DMEM supplemented with 10% FBS (MilliporeSigma). At day 2, cells were switched to DMEM with 10% 
FBS and 1 μg/mL insulin (MilliporeSigma) until day 8. INS-1E rat insulinoma β cells (AddexBio), used for 
no more than 10 passages, were cultured in RPMI-1640 (MilliporeSigma) with 0.02 mM 2-mercaptoeth-
anol and 10% FBS (27). The conditionally immortalized human pancreatic β cell line EndoC-βH3 was 
purchased from Univercell-Biosolutions and cultured according to the manufacturer’s instructions in OPTl 
β1 media containing 10 μg/mL puromycin (52). The cells were seeded onto βCOAT-treated tissue culture 
flasks at 7 × 104 cells/cm2. Inducible excision of  CRE-mediated immortalizing transgenes for GSIS experi-
ments was performed with addition of  1 μM tamoxifen (MilliporeSigma) for 21 days. 3T3-L1, INS-1E, and 
EndoC-βH3 cells were routinely checked by RT-PCR to exclude mycoplasma contamination. All the cells 
were cultured at 37°C in a 5% CO2 humidified atmosphere.
Human pancreatic islets. Human pancreatic islets were isolated from heart-beating cadaveric organ 
donors in the Pancreatic Islet Processing Unit of  the Diabetes Research Institute at the San Raffaele Scien-
tific Institute (Supplemental Table 1) (27). Islet purity was assessed as the percentages of  endocrine clusters 
positive for dithizone staining (range, 80%–90%). After isolation, islets (10,000) were cultured in CMRL 
medium (MilliporeSigma), as previously described (27).
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Human individuals. SAT and OAT explants from 18 obese nondiabetic individuals (13 women and 5 
men, with an average BMI of  39.4 ± 3.7) were obtained during laparoscopic surgery for nonmalignant 
diseases at the Department of  Surgical Sciences, University of  Turin. SAT explants were also obtained 
from 9 lean adult individuals (3 women and 6 men, with an average BMI of  25.7 ± 2) during elective plastic 
surgery of  at the Department of  Reconstructive and Aesthetic Plastic Surgery, University of  Turin.
Isolation and differentiation of  human adipocytes. Adipocyte isolation from SAT explants of  lean subjects 
was performed as described previously (51). Preadipocytes were cultured in DMEM/F12 supplemented 
with 10% FBS until confluence. Then, preadipocyte culture medium was changed to DMEM with 10% 
FBS, 15 mM HEPES, 33 μM biotin, 17 μM pantothenate, 10 μg/mL transferrin, 5 μg/mL human insulin, 1 
μM dexamethasone, and 0.5 mM IBMX for 3 days to initiate differentiation. At day 4, dexamethasone and 
IBMX were removed from the medium and the cells were cultured for a further 21 days before experiments.
Isolation and characterization of  EVs. 3T3-L1 and human adipocytes were cultured in RPMI without 
serum for 24 hours in the presence or absence of  CKs (TNF-α/IFN-γ/IL-1β; 50, 25, and 2.5 ng/mL, 
respectively; PeproTech EC Ltd.). SAT-EVs and OAT-EVs were isolated from fresh human AT specimens. 
Samples were rinsed twice with PBS 1× to remove blood cells, mechanically minced into small pieces, and 
maintained in RPMI medium without serum or growth factors for 24 hours at 37°C in a 5% CO2 humidi-
fied atmosphere. EVs were collected from supernatants. After being centrifuged at 3000g for 20 minutes and 
microfiltered over a 0.22 μm filter (MilliporeSigma) to remove debris, cell-free supernatants derived from 
cell cultures and human AT were ultracentrifuged at 100,000g using a SW70Yi rotor (Beckman Coulter 
Optima L-90K ultracentrifuge) for 2 hours at 4°C. EVs were either used fresh or stored at –80°C after resus-
pension in RPMI supplied with 1% DMSO (v/v). Frozen EVs were washed and pelleted under 100,000g 
ultracentrifugation to remove DMSO before experiments on cells, as previously described (17). EV num-
ber and size distribution analysis was performed using a NanoSight LM10. The particles in the samples 
were illuminated using a laser light source at 405 nm, and the scattered light was captured by camera and 
analyzed using NTA. NTA automatically tracked and sized more than 200 particles, according to Brown-
ian motion and the diffusion coefficient. Results are displayed as number per mL and as frequency size 
distribution graphs, outputted to a spreadsheet. Characterization of  EVs was performed according to the 
criteria suggested by the ISEV (53). Briefly, purified EVs were observed by TEM and analyzed by Western 
blot for the expression of  Alix, CD63, and CD9. Adipocyte markers, such as adiponectin, leptin, FABP4, 
PPARγ-1, and PPARγ-2, were assessed by RT-PCR and Western blot.
TEM. TEM was performed on 3T3-L1–derived EVs (Ad-EVs) and SAT-EVs isolated by ultracentrifu-
gation, resuspended in PBS 1×, placed on 200 mesh nickel formvar carbon-coated grids (Electron Micros-
copy Science), and left to adhere for 20 minutes. Grids were then incubated with 2.5% glutaraldehyde, 
containing 2% sucrose, and EVs were negatively stained with NanoVan (Nanoprobes), after being washed 
in distilled water, and observed under a Jeol JEM 1010 electron microscope.
EV internalization in INS-1E and EndoC-βH3 β cells. The internalization of  EVs into INS-1E and EndoC-
βH3 β cells was evaluated using fluorescent microscopy. A pool of  EVs was labeled with red fluorescent 
PKH26 dye (2 μL/mL; MilliporeSigma) for 30 minutes at 37°C and EVs were then washed and ultracen-
trifuged at 100,000g at 4°C for 1 hour. EV pellets were resuspended in RPMI and used at 5 × 103 EV/target 
cell concentration to INS-1E or EndoC-βH3 β cells and preincubated or not with the anti-CD29 blocking 
monoclonal antibody (1 μg/mL; Santa Cruz Biotechnology) to assess their internalization. Cells were fixed 
with 10% paraformaldehyde, and nuclei were stained with DAPI (1:5000; MilliporeSigma) for 10 minutes 
at 4°C. Images were taken using a Leica DM200 fluorescent microscope and a Leica DFC340 FX camera, 
and analysis performed with a Leica Suite image analysis software.
EV internalization in human pancreatic islets. The internalization of  EVs into human pancreatic islets 
was evaluated using confocal microscopy (LSM5-PASCAL; Zeiss). 1 × 108 EVs were labeled with red flu-
orescent PKH26 dye (2 μL/mL) for 30 minutes at 37°C and then washed and ultracentrifuged at 100,000g 
at 4°C for 1 hour. The EV pellet was resuspended in CMRL medium and added to human pancreatic 
islets (1 × 108 EVs/islet) up to 24 hours to detect internalization. After fixation in 4% paraformaldehyde, 
human pancreatic islets were stained overnight at 4°C with rabbit polyclonal anti-insulin antibody (1:200; 
Abcam). The day after, the cells were incubated for 1 hour at room temperature with Alexa Fluor 488–
conjugated goat anti-rabbit antibody (1:450; Invitrogen). Nuclei were stained with Hoechst 33258 (1:1000; 
MilliporeSigma) for 10 minutes at 4°C. Absence of  primary antibody was used as negative control. Z stack 
confocal microscopy EC images were also obtained.
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Cell survival and proliferation. INS-1E β cells were seeded in 96-well plates at 3 × 103 cells/well and 
cultured for 48 hours, serum starved for 24 hours, and incubated with the different stimuli for a further 
24 hours. Cell survival and proliferation were assessed using the MTT assay (MilliporeSigma) and 5-bro-
mo-2-deoxyuridine (BrdU) incorporation ELISA kit (Roche Diagnostics), respectively, as previously 
described (27, 51). Human pancreatic islets were seeded in 96-well plates (3 islets/well) and cultured for 
48 hours, serum starved for 24 hours, and incubated with the different stimuli for a further 72 hours. Cell 
survival was assessed by Alamar blue assay (MilliporeSigma), as previously described (27). EndoC-βH3 β 
cells were seeded in 96-well plates at 10 × 103 cells/well, cultured for 48 hours, and incubated with different 
stimuli for a further 24 hours in OPTlβ1 media. Cell survival was assessed by MTT assay. Absorbance was 
assessed by spectrophotometry at 570 nm for MTT and Alamar and at 450 nm for BrdU, using a LT-4000 
microplate reader (Euroclone).
Caspase-3 activity. INS-1E β cells were seeded in 6-well plates at 5 × 104 cells/well. After 48 hours the 
cells were serum starved for 24 hours and incubated with Ad-EVs or EVs obtained from CK-EVs for an 
additional 24 hours. Caspase-3 activity was assessed by the Caspase-3 Colorimetric Assay Kit (BioVision) 
in cell lysates, according to the manufacturer’s instructions, and analyzed by colorimetric detection at 450 
nm absorbance with a LT-4000 microplate reader (Euroclone).
Western blotting. 3T3-L1 adipocytes, INS-1E β cells, SAT, Ad-EVs, and SAT-EVs were lysed in RIPA 
buffer (MilliporeSigma), and protein concentrations were calculated as previously described (27). Proteins 
(70 μg) were resolved in 11% SDS-PAGE (15% for CD9, leptin, and FABP4) and transferred to a nitrocellu-
lose membrane. After blocking with 5% BSA in Tris-buffered saline with 0.1% Tween (MilliporeSigma) for 
1 hour at room temperature, membranes were incubated overnight at 4°C with the specific antibody (Alix, 
CD63, CD9, adiponectin, leptin, FABP4, PPARγ, phospho-Akt (P-Akt) (Ser473), P-glycogen synthase 
kinase 3β (P-GSK-3β) (Ser9), P-ERK1/2 (Thr202/Tyr204), P-PERK (Thr980), P-eIF2α (Ser51), P-SAPK/
JNK (Thr183/Tyr185), and actin (dilution 1:1000; leptin, FABP4, PPARγ, and actin, 1:500). Blots were 
reprobed with the respective total antibodies or actin for normalization. Immunoreactive proteins were 
visualized using horseradish peroxidase–conjugated goat anti-mouse or goat anti-rabbit (1:4000) antibodies 
(SouthernBiotech) by enhanced chemiluminescence using ChemiDoc XRS (Bio-Rad). Each experiment 
was performed in triplicate. Densitometric analysis was carried out with Quantity One software (Bio-Rad). 
(See Supplemental Table 2 for detailed information on antibodies.)
GSIS. GSIS in INS-1E β cells and human pancreatic islets was performed as previously described (27). 
Briefly, INS-1E β cells (5 × 105 cells) and human pancreatic islets (n = 3) were serum starved for 24 hours 
and then incubated for 1 hour at 37°C in HEPES-buffered Krebs-Ringer bicarbonate buffer (MilliporeSig-
ma) containing 0.5% BSA and 2 mM glucose (MilliporeSigma). The medium was changed, and the cells 
were incubated for 1 hour in Krebs-Ringer bicarbonate buffer/0.5% BSA containing 1.25, 7.5, and 15 
mM glucose, with or without Ad-EVs or CK-EVs (10 × 103/cell). Insulin release from INS-1E β cells and 
human pancreatic islets was quantified by the rat Insulin ELISA kit (Tebu-Bio) and human IRMA Insulin 
kit (Pantec), respectively, following the manufacturer’s instructions. After excision of  CRE transgenes by 
tamoxifen (1 μM; MilliporeSigma) for 21 days, GSIS in EndoC-βH3 β cells was evaluated according the 
manufacturer’s instructions. Briefly, EndoC-βH3 β cells were incubated with βKREBS BSA buffer for 1 
hour, then for an additional hour with 1.25, 15, and 25 mM glucose in either absence or presence of  sAd-
EVs and SAT-EVs or OAT-EVs (10 × 103/cell). Insulin secretion was assessed by the Insulin ELISA kit 
(Mercodia) following the manufacturer’s instructions.
RT-PCR and real-time PCR. Total RNA isolation and reverse transcription to cDNA (3 μg RNA 
for RT-PCR and 1 μg RNA for real-time PCR) from 3T3-L1 adipocytes, INS-1E cells, EndoC-βH3 
cells, SAT, Ad-EVs, and SAT-EVs treated with TRIzol reagent (Life Technologies) were performed as 
described previously (27). For RT-PCR, 9 μL cDNA was amplified in a 50 μL volume using AmpliTaq 
Gold Polymerase in a GeneAmp PCR System (PerkinElmer). Amplifications were assessed in the fol-
lowing conditions: 95°C for 30 seconds, annealing for 30 seconds (55°C for adiponectin and FABP4; 
57°C for leptin; 56°C for PPAR-γ1; and 54°C for PPAR-γ2), 72°C for 60 seconds, and 72°C for 7 min-
utes for the elongation step. The final PCR products for adiponectin (mouse,122 bp; human,110 bp), 
leptin (mouse,181 bp; human, 211 bp), FABP4 (mouse,151 bp; human,154 bp), PPAR-γ1 (mouse, 214 
bp; human, 150 bp), PPAR-γ2 (mouse, 350 bp; human, 123 bp), and 18S rRNA (120 bp) were separated 
by 2% agarose gel electrophoresis and visualized by ethidium bromide staining. 3T3-L1 adipocytes and 
SAT were used as positive control. 18S rRNA served as internal control; the negative control consisted 
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of  no RNA. For real-time PCR, cDNAs were treated with DNA-free DNase (Life Technologies), and 
the reaction was performed with 50 ng cDNA, 100 nM of  each primer, and IQ-SYBR-green Mastermix 
(Bio-Rad) using the ABI-Prism 7300 (Applied Biosystems). 18S rRNA was used as endogenous con-
trol. Relative quantification was performed using the comparative Ct (2−ΔΔCt) method. Primers were 
designed with Primer 3 Software (http://www.primer3.org/), and sequences and details are reported in 
Supplemental Tables 3 and 4.
Adiponectin secretion. Adiponectin levels were measured in INS-1E β cell–concentrated (18-fold) condi-
tioned medium using the Adipoq ELISA Kit (Abnova, Tebu-bio s.r.l), following the manufacturer’s instruc-
tions. 3T3-L1 adipocyte–conditioned medium was used as positive control.
Library preparation for small RNA-Seq. Total RNA from 3T3-L1–derived Ad-EVs and CK-EVs, and sAd-
EVs and sCK-EVs from subcutaneous human differentiated adipocytes, was extracted with mirVana kit 
(Ambion, Life Technologies) according to the manufacturer’s instructions. RNA was quantified by Qubit 
2.0 Fluorometer with the Qubit microRNA Assay Kit (Invitrogen) according to MIQE guidelines (http://
miqe.gene-quantification.info/). Small RNA transcripts were converted into barcoded cDNA libraries with 
the NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England BioLabs Inc.), as previ-
ously described (54) and according to the manufacturer’s protocol (protocol E7330, New England BioLabs 
Inc.). Libraries were pooled together (24 plex) and subjected to the Illumina sequencing pipeline, pass-
ing through clonal cluster generation on a single-read flow cell (Illumina Inc.) and 75 cycles of  sequenc-
ing-by-synthesis on the Illumina Next-Seq 500. Computational miRNA data analysis was performed fol-
lowing the previously described optimized workflow (54). Raw sequencing data were deposited on Gene 
Expression Omnibus (GSE158654). Further details are provided in the Supplemental Methods.
Statistics. Results are expressed as mean ± SEM. Statistical significance was determined using 1-way ANO-
VA with Tukey’s or Dunnett’s post hoc analysis for multiple groups or unpaired 2-tailed Student’s t test to 
compare 2 groups when appropriate. Wald’s test with Benjamini-Hochberg false discovery rate correction for 
multiple testing was used for RNA-Seq. Statistical analysis was performed with GraphPad Prism 5.0 Software 
and R package DESeq2 1.22.2 (http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html). 
Expression levels of significantly differently expressed miRNAs were displayed using the R package pheat-
map. miRNA functional enrichment analysis was performed using EnrichR web tool (https://maayanlab.
cloud/Enrichr/, ref. 55) on the list of  validated miRNA targets annotated in the miRWalk 2.0 database 
(http://mirwalk.umm.uni-heidelberg.de/, ref. 34). Significance was established at P < 0.05.
Study approval. Human pancreatic islets were isolated from heart-beating cadaveric organ donors in the 
Pancreatic Islet Processing Unit of  the Diabetes Research Institute at the San Raffaele Scientific Institute. 
The use of  human pancreatic islets (islet preparations discarded from clinical use) was approved by the 
institutional review board of  the San Raffaele Scientific Institute under the “European Consortium for 
Islet Transplantation (ECIT), human islet distribution program,” supported by the JDRF (3-RSC-2016-
160-I-X). The study protocol for the use of  human AT explants was approved by the ethics committee of  
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy (CS/100 – pro-
tocol 12175; February 4, 2014)], and all the individuals provided informed written consent before surgery.
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